Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Sept. 28, 2016 -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 3, 2016 in the lawsuit that was filed for certain investors in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) over alleged Securities Laws Violations by Keryx Biopharmaceuticals.
The lawsuit seeks to recover damages for certain NASDAQ:KERX investors.
Investors who purchased shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have certain options should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product, that the issue was resulting in decreased production yields of finished drug product, that, as a result, the Company would, and did exhaust its reserve of finished drug product, and that, as a result of the foregoing, Defendants’ statements about Keryx Biopharmaceuticals’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Those who purchased Keryx Biopharmaceuticals (NASDAQ:KERX) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
